Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Unit Trust
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: Global

AXA Framlington Biotech Fund

+ Add to Watchlist

FRABIOA:LN

166.00 GBp 1.20 0.72%

As of 00:59:30 ET on 03/02/2015.

Snapshot for AXA Framlington Biotech Fund (FRABIOA)

Year To Date: +11.63% 3-Month: +15.20% 3-Year: +42.75% 52-Week Range: 95.62 - 167.20
1-Month: +1.41% 1-Year: +35.85% 5-Year: +28.71% Beta vs NBI: 0.94

Mutual Fund Chart for FRABIOA

No chart data available.
  • FRABIOA:LN 166.00
  • 1M
  • 1Y
Interactive FRABIOA Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for FRABIOA

AXA Framlington Biotech Fund is an authorized unit trust incorporated in the United Kingdom. The aim of the Fund is to provide long-term capital appreciation The Fund will invest principally in equity securities of companies in the biotechnology, genomic and medical research industries worldwide.

Inception Date: 11-26-2001 Telephone: 44-207-374-4100
Managers: LINDEN THOMSON / GEMMA GAME
Web Site: www.axa-framlington.com

Fundamentals for FRABIOA

NAV (on 2015-03-02) 166.00
Assets (M) (on 2014-12-31) 520.60
Fund Leveraged N
Minimum Investment 1,000.00
Minimum Subsequent Investment 100.00

Dividends for FRABIOA

Dividend Type Omitted
Dividend Frequency Semi-Anl
Last Dividend Net -
Dividend Yield (ttm) -

Fees & Expenses for FRABIOA

Front Load 5.50
Back Load 0.00
Current Mgmt Fee 1.75
Redemption Fee 0.00
12b1 Fee -
Expense Ratio 1.95

Top Fund Holdings for FRABIOA

Filing Date: 01/30/2015
Name Position Value % of Total
Biogen Idec Inc 219,640 56,907,600 9.400%
Celgene Corp 709,684 56,302,200 9.300%
Gilead Sciences Inc 641,887 44,799,600 7.400%
Amgen Inc 438,271 44,194,200 7.300%
Illumina Inc 214,295 27,848,400 4.600%
Vertex Pharmaceuticals Inc 346,750 25,426,800 4.200%
Regeneron Pharmaceuticals Inc 87,295 24,216,000 4.000%
Alexion Pharmaceuticals Inc 198,496 24,216,000 4.000%
BioMarin Pharmaceutical Inc 290,126 18,767,400 3.100%
Incyte Corp 342,232 18,162,000 3.000%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil